Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 7, 1999, Pages 1616-1620

  Calfee, David P ^a   Peng, Amy W ^b   Cass, Lindsey M ^b   Lobo, Monica ^a   Hayden, Frederick G ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIALIDASE; SODIUM CHLORIDE; ZANAMIVIR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; VIRUS SHEDDING;

EID: 0032779292     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.7.1616     Document Type: Article

References (17)

1. Aoki, D., F. Fleming, L. Lacey, O. Keene, M. Keech, and P. Macleod. 1997. Impact of treatment of influenza with zanamivir on patients' health status, sleep quality, productivity and healthcare use, abstr. N-15, p. 384. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. 1a. Calfee, D. P., A. W. Peng, L. M. R. Cass, M. Lobo, and F. G. Hayden. 1998. Protective efficacy of intravenous zanamivir in experimental human influenza, abstr. H-58, p. 332. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Colman, P. M. 1994. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 3:1687-1696.
4. Efthymiopoulos, C., P. Barrington, J. Patel, A. Harker, E. K. Hussey, and A. Bye. 1994. Pharmacokinetics of the neuraminidase inhibitor 4-guanidino Neu5Ac2en (GG167) following intravenous, intranasal and inhaled administration in man, abstr. H70, p. 265. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. 3a. Glaxo Wellcome, Inc. Unpublished data.
6. Gubareva, L. V., C. R. Penn, and R. G. Webster. 1995. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 212:323-330.
7. Hayden, F. G., M. Lobo, E. K. Hussey, et al. 1996. Efficacy of intranasal GG167 in experimental human influenza A and B virus infections, p. 718-725. In L. E. E. Brown, A. W. Hampson, and R. G. Webster (ed.), Options for the control of influenza III. Elsevier Science Publishing, Inc., New York, N.Y.
8. Hayden, F. G., D. M. E. Osterhaus, J. J. Treanor, D. M. Fleming, F. Y. Aoki, K. G. Nicholson, A. M. Bohnen, H. M. Hirst, O. Keene, and K. Wightman. 1997. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N. Engl. J. Med. 337:874-880.
9. Hayden, F. G., B. S. Rollins, and L. K. Madren. 1994. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antivir. Res. 25:123-131.
10. Hayden, F. G., J. J. Treanor, R. F. Betts, M. Lobo, J. D. Esinhart, and E. K. Hussey. 1996. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 274:295-299.
11. Matsumoto, K., K. Nerome, Y. Numasaki, et al. 1996. Inhaled and intranasal GG167 in the treatment of influenza A and B: preliminary results, p. 713-717. In L. E. Brown, A. W. Hampson, and R. G. Webster (ed.), Options for the control of influenza III. Elsevier Science Publishing, Inc., New York, N.Y.
12. 9a. Monto, A. S., D. P. Robinson, L. Herlocher, J. M. Hinson, M. Elliott, and O. Keene. 1998. Efficacy and safety of zanamivir in prevention of influenza among healthy adults, abstr. LB-7, p. 22. In Final program, abstracts, and exhibits (addendum) of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Ryan, D. M., J. Ticehurst, M. H. Dempsey, and C. R. Penn. 1994. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. 38:2270-2275.
14. Sidwell, R. W., J. H. Huffman, D. L. Barnard, K. W. Bailey, M. H. Wong, A. Morrison, T. Syndergaard, and C. U. Kim. 1998. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antivir. Res. 37:107-120.
15. Thomas, G. P., M. Forsyth, C. R. Penn, and J. W. McCauley. 1994. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antivir. Res. 24:351-356.
16. Walker, J. B., E. K. Hussey, J. J. Treanor, A. Montalvo, Jr., and F. G. Hayden. 1997. Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J. Infect. Dis. 176:1417-1422.
17. Woods, J. M., R. C. Bethell, J. A. V. Coates, N. Healy, S. A. Hiscox, B. A. Pearson, D. M. Ryan, J. Ticehurst, J. Tilling, S. M. Walcott, and C. R. Penn. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1473-1479.